LCD-L36889
Document details
Summary
The recent LCD for cardiovascular stress testing emphasizes the necessity for compliance with updated guidelines, which may impact reimbursement. Providers must ensure correct documentation and codingStay compliant with new stress testing billing guidelines.
Affected codes
ICD-10-CM
Affected specialty
Cardiology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36889&ver=25CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA202155 · Cardiology
Eliquis (apixaban) is an oral anticoagulant approved as a tablet (including a tablet for suspension formulation), which routes it through Medicare Part D for outpatient prescription coverage. As an or
View alertPolicy FDA-NDA220073 · Cardiology
Eliquis (apixaban) has received approval for a new oral suspension dosage form under NDA220073, expanding access for patients unable to swallow tablets—likely pediatric or dysphagic populations. As an
View alertPolicy FDA-NDA022434 · Cardiology
Argatroban in sodium chloride is an injectable medication that will likely receive a J-code for billing purposes under Medicare Part B. As an intravenous drug, it may also qualify for pass-through pay
View alertPolicy LCD-L40255 (Notice Ends 06/20/2026) · Cardiology
This final LCD from Noridian (JE/JF) governs coverage of temporary nontherapeutic ambulatory cardiac monitoring devices across 15 western states, effective June 21, 2026. It defines coverage criteria
View alert